Macropore Inc. IR-Pages
MacroPore Biosurgery Updates its Financial Outlook for 2004
Ad-hoc-announcement transmitted by DGAP.
The issuer is solely responsible for the content of this announcement.
——————————————————————————–
MacroPore Biosurgery Updates its Financial Outlook for 2004 and Announces
Preliminary Second Quarter Revenues
San Diego, CA, July 19, 2004 – MacroPore Biosurgery, Inc. (Frankfurt: XMP)
(Reuters: MACP.DE) (Bloomberg: XMP) today announced that it is withdrawing its
previously stated 2004 revenue guidance because the Company is currently not in
a position to reliably project HYDROSORB(TM) product revenues based on the
information available at this time. The HYDROSORB(TM) products are distributed
exclusively through Medtronic Sofamor Danek (MSD).
Preliminary revenues for the quarter ended June 30, 2004 are expected to be
approximately $1.5 million, with approximately $887,000 attributable to the
HYDROSORB(TM) spine and orthopedic product line. For the six-months ended June
30, 2004, preliminary revenues are expected to be $3.9 million, with
approximately $2.5 million attributable to the HYDROSORB(TM) line. MacroPore
Biosurgery expects to end the quarter with cash and cash equivalents and short-
term investments of $18.0 million.
end of ad-hoc-announcement (c)DGAP 19.07.2004
Issuer’s information/explanatory remarks concerning this ad-hoc-announcement:
“We will continue to support the long-term adoption of this technology in
conjunction with MSD, despite the difficulty anticipating adoption rates in the
market and the purchases from MSD,” said Christopher J. Calhoun, Chief Executive
Officer of MacroPore Biosurgery. “Importantly, MSD has reaffirmed their
commitment to this product line over the long-term. The outstanding performance
of HYDROSORB(TM), as detailed in the recently published journal, Neurosurgical
Focus, and the advantages it offers as a resorbable technology suggest that this
product family will play an important clinical role in the future.”
“The other components of our business, in particular, the regenerative cell
technology program, have continued to perform at or above expectations thus far
this year,” added Mr. Calhoun. “The accomplishments include achieving multiple
regulatory, scientific and business development milestones, such as the pre-
clinical data we released that suggests adipose-derived regenerative cells have
the potential to engraft and differentiate into heart muscle, and the recent
sale of our thin film business. We expect to continue this success throughout
the second half.”
The management of MacroPore Biosurgery will host a conference call today at 4:30
pm Central Eastern Summer Time (CEST) or 10:30 am Eastern Daylight Time (EDT)
to discuss the updated outlook and preliminary revenues. This conference call
may be accessed from the investor relations section of the Company’s website,
www.macropore.com. An archived version of the webcast will be available on the
same website 60 minutes after the call. The audio replay will be archived for 24
hours following the call and may be accessed by dialing +49 69 58 99 90 568
(PIN: 132637#) or (303) 590-3000 (PIN: 11003580#).
MacroPore Biosurgery will release the full second quarter results on August 16,
2004 at approximately 4:00 PM CEST and host a conference call to discuss the
results at 4:30 PM CEST that same day.
About MacroPore Biosurgery, Inc.
MacroPore Biosurgery (Frankfurt: XMP) is focused on the discovery, development
and commercialization of regenerative medicine technologies. We have two
technology platforms, bioresorbable technology and regenerative cell technology.
Our surgical implants, derived from our bioresorbable technology, represent one
of the latest advancements in spine and orthopedic medicine. They are
manufactured by us and distributed exclusively through Medtronic Sofamor Danek.
Within our regenerative cell technology program, we are developing a system to
isolate autologous, homologous-use, regenerative cells. Simultaneously, we are
generating scientific knowledge through internal research to support the
clinical use of these cells. Our most advanced research and development program
is in the repair of cardiovascular tissues that are damaged after a heart
attack. We are also researching applications in bone repair, spinal disc
regeneration, and cosmetic and reconstructive surgery. For further information
please visit our web site http://www.macropore.com .
Cautionary Statement Regarding Forward-Looking Statements
This press release may include forward-looking statements regarding events and
trends which may affect MacroPore Biosurgery’s future operating results and
financial position. Such statements are subject to risks and uncertainties that
could cause MacroPore Biosurgery’s actual results and financial position to
differ materially. These risks and uncertainties are described (under the
heading “Risk Factors”) in our 2003 Form 10-K annual report for the year ended
December 31, 2003, which is available on our web site. MacroPore Biosurgery
assumes no responsibility to update any revision of forward-looking statements
to reflect events, trends or circumstances after the date they are made.
Contact:
MacroPore Biosurgery, Inc.
Tom Baker
Media & U.S. Investors
Tel. +1-858-458-0900
tbaker@macropore.com
MacroPore Biosurgery, Inc.
Stefanie Bacher
European Investors
Tel. +1-858-362-0365
sbacher@macropore.com
edicto GmbH
Axel Mühlhaus/Sönke Knop
European Investor &
Press Agency
Tel.: +49 (0) 60 84 94 85-90
kontakt@edicto.de
——————————————————————————–
WKN: 940682; ISIN: USU553961025; Index: NEMAX 50
Listed: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin-
Bremen, Düsseldorf, Hamburg, Hannover und Stuttgart
191600 Jul 04
Latest News
Latest Reports
Upcoming Events
No Events found
Webcasts
No Webcasts found